Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin | Zendy

Steven J. Czinn | Zendy; Howard S. Carr | Zendy; Stephen C. Aronoff | Zendy

Open Access

Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin

Author(s) -

Steven J. Czinn,

Howard S. Carr,

Stephen C. Aronoff

Publication year - 1986

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.30.2.328

Subject(s) - roxithromycin , erythromycin , campylobacter , antibiotics , microbiology and biotechnology , microgram , macrolide antibiotics , minimum inhibitory concentration , medicine , campylobacter jejuni , pharmacology , chemistry , biology , bacteria , in vitro , biochemistry , genetics

The presence of Campylobacter pyloridis in the gastric mucosa was recently linked to peptic ulcer disease. This study compared the inhibitory activity of three macrolide compounds (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin against 10 clinical isolates of C. pyloridis. The macrolides were equally effective against the test strains, with MICs ranging from 0.06 to 0.5 microgram/ml; rifampin was less active, with MICs ranging from 0.25 to greater than 1 microgram/ml. Erythromycin and the two new macrolide derivatives are potentially useful agents in the treatment of infections caused by C. pyloridis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research